[HIGHLIGHTS] All units of two batches of an angina drug recalled for a defect that does not pose "serious or life-threatening risk"

The Spanish Agency for Medicines and Health Products (Aemps) has withdrawn two batches of the drug Cafinitrin. The drug is used to treat and prevent angina.

A quality defect does not pose a "serious or life-threatening risk" to the patient, Aemps said. The batches affected by this defect are T009 and T010, both with an expiration date of August 31, 2025, of Cafinitrina sublingual coated tablets, manufactured and marketed by Kern Pharma.